De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials
Top Cited Papers
- 31 August 2024
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 404 (10456) , 937-948
Abstract
No abstract availableKeywords
Funding Information
- Istituto Cardiocentro Ticino
- Ente Ospedaliero Cantonale
This publication has 26 references indexed in Scilit:
- Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary InterventionJAMA Cardiology, 2024
- Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CADJACC: Cardiovascular Interventions, 2020
- Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary SyndromeJAMA, 2020
- Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary StentingJACC, 2019
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary InterventionJAMA, 2019
- Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary StentingJACC, 2019
- Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trialsThe Lancet, 2017
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant DataJAMA, 2015
- Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysisJournal of Clinical Epidemiology, 2008